Identification of distant drug off-targets by direct superposition of binding pocket surfaces

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Schumann, Marcel ^a   Armen, Roger S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; CDC LIKE KINASE 3; ESTROGEN RECEPTOR BETA; GLUCOCORTICOID RECEPTOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE 5A; PHOSPHOTRANSFERASE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISTANT DRUG OFF TARGET; DRUG TARGETING; LIGAND BINDING; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DATA BANK; PROTEIN TARGETING;

BINDING SITES; CASEIN KINASE II; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DATABASES, PROTEIN; DRUG DESIGN; ESTROGEN RECEPTOR BETA; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, GLUCOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84896717365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083533     Document Type: Article

References (66)

1. Binkowski TA, Joachimiak A (2008) Protein functional surfaces: Global shape matching and local spatial alignments of ligand binding sites. BMC Structural Biology 8: 45.
2. Tseng YY, Chen ZJ, LiWH (2009) fpop: footprinting functional pockets of proteins by comparative spatial patterns. Nucleic Acids Research 38.
3. Andersson DC, Chen BY, Linusson A (2010) Mapping of ligand-binding cavities in proteins. Proteins 78: 1408-1422.
4. Chikhi R, Sael L, Kihara D (2010) Real-time ligand binding pocket database search using local surface descriptors. Proteins: Structure, Function, and Bioinformatics 78: 2007-2028.
5. Ito JI, Tabei Y, Shimizu K, Tsuda K, Tomii K (2012) Possum: a database of similar proteinligand binding and putative pockets. Nucleic Acids Research 40: D541-D548.
6. Spitzer R, Cleves AE, Jain AN (2011) Surface-based protein binding pocket similarity. Proteins: Structure, Function, and Bioinformatics 79: 2746-2763.
7. Xie L, Xie L, Bourne PE (2009) A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics 25: i305-i312.
8. Xie L, Li J, Xie L, Bourne PE (2009) Drug discovery using chemical systems biology: Identification of the protein-ligand binding network to explain the side effects of cetp inhibitors. PLoS Comput Biol 5: e1000387.
9. Kuhn D, Weskamp N, Schmitt S, Hllermeier E, Klebe G (2006) From the similarity analysis of protein cavities to the functional classification of protein families using cavbase. Journal of Molecular Biology 359: 1023-1044. (Pubitemid 43842050)
10. Sael L, Kihara D (2012) Detecting local ligand-binding site similarity in nonhomologous proteins by surface patch comparison. Proteins 80: 1177-1195.
11. Konc J, Janei D (2010) Probis algorithm for detection of structurally similar protein binding sites by local structural alignment. Bioinformatics 26: 1160-1168.
12. Milletti F, Vulpetti A (2010) Predicting polypharmacology by binding site similarity: From kinases to the protein universe. Journal of Chemical Information and Modeling 50: 1418-1431.
13. Najmanovich R, Kurbatova N, Thornton J (2008) Detection of 3d atomic similarities and their use in the discrimination of small molecule protein-binding sites. Bioinformatics 24: i105-i111.
14. Hoffmann B, Zaslavskiy M, Vert JP, Stoven V (2010) A new protein binding pocket similarity measure based on comparison of clouds of atoms in 3d: application to ligand prediction. BMC Bioinformatics 11: 99.
15. Schumann M, Armen RS (2013) Systematic and efficient side chain optimization for molecular docking using a cheapest-path procedure. Journal of Computational Chemistry 34: 1258-1269.
16. Connolly ML (1983) Analytical molecular surface calculation. Journal of Applied Crystallography 16: 548-558.
17. Katchalski-Katzir E, Shariv I, Eisenstein M, Friesem AA, Aflalo C, et al. (1992) Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques. Proceedings of the National Academy of Sciences 89: 2195-2199.
18. Papoulis A (1962) The Fourier Integral and Its Applications. McGraw-Hill, 245-253 pp.
19. Karaman M, Herrgard S, Treiber D, Gallant P, Atteridge C, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology 26: 127-132.
20. Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22. pp. 2577-2637.
21. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK (2007) Bindingdb: a web-accessible database of experimentally determined proteinligand binding affinities. Nucleic Acids Research 35: D198-D201. (Pubitemid 46056198)
22. Duncan PI, Stojdl DF, Marius RM, Scheit KH, Bell JC (1998) The clk2 and clk3 dual-specificity protein kinases regulate the intranuclear distribution of sr proteins and influence pre-mrna splicing. Exp Cell Res 241: 300-308. (Pubitemid 28366555)
23. Eisenreich A, Bogdanov VY, Zakrzewicz A, Pries A, Antoniak S, et al. (2009) Cdc2-like kinases and dna topoisomerase i regulate alternative splicing of tissue factor in human endothelial cells. Circ Res 104: 589-599.
24. Mukherjee R, Jow L, Croston GE, Paterniti JR (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (ppar) isoforms ppargamma2 versus ppargamma1 and activation with retinoid x receptor agonists and antagonists. J?Biol Chem 272: 8071-8076. (Pubitemid 27137374)
25. Erbe DV, Wang S, Zhang YL, Harding K, Kung L, et al. (2005) Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Molecular Pharmacology 67: 69-77. (Pubitemid 40069967)
26. Otake K, Azukizawa S, Fukui M, Kunishiro K, Kamemoto H, et al. (2012) Novel (s)-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acids: Peroxisome proliferator-activated receptor selective agonists with protein-tyrosine phosphatase 1b inhibition. Bioorganic & Medicinal Chemistry 20: 1060-1075.
27. Shrestha S, Bhattarai BR, Cho H, Choi JK, Cho H (2007) Ptp1b inhibitor ertiprotafib is also a potent inhibitor of ib kinase β (ikk-β). Bioorganic & Medicinal Chemistry Letters 17: 2728-2730. (Pubitemid 46636263)
28. Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, et al. (2007) Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor γ activity: A combined virtual screening and biological assay approach. Molecular Pharmacology 71: 398-406. (Pubitemid 46147906)
29. Amano Y, Yamaguchi T, Ohno K, Niimi T, Orita M, et al. (2012) Structural basis for telmisartanmediated partial activation of ppar gamma. Hypertension Research 35: 715-719.
30. Singh B, Sharma B, Jaggi AS, Singh N (2013) Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of alzheimers disease type: possible involvement of ppar-γ agonistic property. Journal of Renin-Angiotensin-Aldosterone System 14: 124-136.
31. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, et al. (2008) Angiotensin inhibition stimulates ppar c and the release of visfatin. European Journal of Clinical Investigation 38: 820-826.
32. Cho M, Lee H, Kim J, Choe Y, Hong J, et al. (2003) A simple elisa for screening ligands of peroxisome proliferator-activated receptor gamma. Journal of biochemistry and molecular biology 36: 207-213.
33. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, et al. (1992) Identification of the kdr tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586.
34. Urlaub G, Chasin L (1980) Isolation of chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proceedings of the National Academy of Sciences 77: 4216-4220. (Pubitemid 10022580)
35. Gangjee A, Li W, Lin L, Zeng Y, Ihnat M, et al. (2009) Design, synthesis, and x-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors. Bioorganic & Medicinal Chemistry 17: 7324-7336.
36. Edling CE, Hallberg B (2007) c-kit-a hematopoietic cell essential receptor tyrosine kinase. The International Journal of Biochemistry & Cell Biology 39: 1995-1998. (Pubitemid 47376824)
37. Kohl N, Emini E, Schleif W, Davis L, Heimbach J, et al. (1988) Active human immunodeficienc virus protease is required for viral infectivity. Proceedings of the National Academy of Sciences 85: 4686-4690.
38. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnology 29: 10461051.
39. Xie L, Evangelidis T, Xie L, Bourne PE (2011) Drug discovery using chemical systems biology: Weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol 7: e1002037.
40. Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, et al. (2011) Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine b: Modulation of alternative pre-rna splicing. Journal of Medicinal Chemistry 54: 4172-4186.
41. Wickens P, Zhang C, Ma X, Zhao Q, Amatruda J, et al. (2007) Indanylacetic acids as ppar-δactivator insulin sensitizers. Bioorganic & Medicinal Chemistry Letters 17: 4369-4373. (Pubitemid 47021375)
42. Morphy R (2010) Selectively nonselective kinase inhibition: Striking the right balance. Journal of Medicinal Chemistry 53: 1413-1437.
43. Gangjee A, Li W, Lin L, Zeng Y, Ihnat M, et al. (2009) Design, synthesis, and x-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors. Bioorganic & Medicinal Chemistry 17: 7324-7336.
44. Dorsey BD, McDonough C, McDaniel SL, Levin RB, Newton CL, et al. (2000) Identification of mk-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of hiv protease inhibitors. Journal of Medicinal Chemistry 43: 3386-3399.
45. Fabre S, Prudhomme M, Rapp M (1992) Preparation of synthons for the synthesis of protein kinase c inhibitors from rebeccamycin. Bioorganic & Medicinal Chemistry Letters 2: 449-452.
46. Zembower DE, Zhang H, Lineswala JP, Kuffel MJ, Aytes SA, et al. (1999) Indolocarbazole poisons of human topoisomerase i: Regioisomeric analogues of ed-110. Bioorganic & Medicinal Chemistry Letters 9: 145-150. (Pubitemid 29059517)
47. Ukita T, Nakamura Y, Kubo A, Yamamoto Y, Moritani Y, et al. (2001) Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1- isoquinolinone derivatives. Journal of Medicinal Chemistry 44: 2204-2218. (Pubitemid 32861779)
48. Hagishita S, Yamada M, Shirahase K, Okada T, Murakami Y, et al. (1996) Potent inhibitors of secretory phospholipase a2: synthesis and inhibitory activities of indolizine and indene derivatives. Journal of Medicinal Chemistry 39: 3636-3658. (Pubitemid 26307871)
49. Norman BH, Richardson TI, Dodge JA, Pfeifer LA, Durst GL, et al. (2007) Benzopyrans as selective estrogen receptor β agonists (serbas). part 4: Functionalization of the benzopyran a-ring. Bioorganic & Medicinal Chemistry Letters 17: 5082-5085. (Pubitemid 47260738)
50. Innocenti A, Glin I, Scozzafava A, Supuran CT (2010) Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms ixv. Bioorganic & Medicinal Chemistry Letters 20: 5050-5053.
51. Onnis V, Kinsella GK, Carta G, Jagoe WN, Price T, et al. (2010) Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators. Journal of Medicinal Chemistry 53: 3065-3074.
52. Kurz M, Brachvogel V, Matter H, Stengelin S, Thring H, et al. (2003) Insights into the bile acid transportation system: The human ileal lipid-binding protein-cholyltaurine complex and its comparison with homologous structures. Proteins: Structure, Function, and Bioinformatics 50: 312-328. (Pubitemid 36055609)
53. St-Denis NA, Derksen DR, Litchfield DW (2009) Evidence for regulation of mitotic progression through temporal phosphorylation and dephosphorylation of ck2alpha. Mol Cell Biol 29: 2068-2081.
54. Sayed M, Pelech S, Wong C, Marotta A, Salh B (2001) Protein kinase ck2 is involved in g2 arrest and apoptosis following spindle damage in epithelial cells. Oncogene 20: 6994-7005. (Pubitemid 33052192)
55. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, et al. (2002) The mechanism of topoisomerase i poisoning by a camptothecin analog. Proceedings of the National Academy of Sciences 99: 15387-15392. (Pubitemid 35403944)
56. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, et al. (1998) Isolation and characterization of cdnas encoding pde5a, a human cgmp-binding, cgmp-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216: 139-147. (Pubitemid 28389111)
57. Magrioti V, Kokotos G (2010) Phospholipase a2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opinion on Therapeutic Patents 20: 1-18.
58. Sanchez-Mejia RO, Mucke L (2010) Phospholipase a2 and arachidonic acid in alzheimer's disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1801: 784-790.
59. White M, McHowat J (2007) The therapeutic potential of phospholipasea2 inhibitors in cardiovascular disease. Cardiovascular & hematological agents in medicinal chemistry 5: 91-95. (Pubitemid 46062425)
60. Rosenson RS, Fraser H, Trias J, Hislop C (2010) Varespladib methyl in cardiovascular disease. Expert Opinion on Investigational Drugs 19: 1245-1255.
61. Singh N, Jabeen T, Sharma S, Somvanshi RK, Dey S, et al. (2006) Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7Å resolution. Acta Crystallographica Section?D 62: 410-416.
62. Mäkelä A, Kuusi T, Schröder T (1997) Inhibition of serum phospholipase-a2 in acute pancreatitis by pharmacological agents in vitro. Scandinavian journal of clinical & laboratory investigation 57: 401-407.
63. Sano A, Munoz N, Sano H, Choi J, Zhu Z, et al. (1999) Inhibition of cpla2 translocation and leukotriene c4 secretion by fluticasone propionate in exogenously activated human eosinophils. American Journal of Respiratory and Critical Care Medicine 159: 1903-1909. (Pubitemid 29275062)
64. Myo S, Zhu X, Myou S, Meliton A, Liu J, et al. (2004) Additive blockade of 2integrin adhesion of eosinophils by salmeterol and fluticasone propionate. European Respiratory Journal 23: 511-517. (Pubitemid 38455989)
65. Myo S, Zhu X, Myou S, Meliton A, Liu J, et al. (2004) Additive blockade of 2integrin adhesion of eosinophils by salmeterol and fluticasone propionate. European Respiratory Journal 23: 511-517. (Pubitemid 38455989)
66. Grataroli R, Leonardi J, Chautan M, Lafont H, Nalbone G (1993) Effect of anthracyclines on phospholipase a2 activity and prostaglandin e2 production in rat gastric mucosa. Biochemical Pharmacology 46: 349-355. (Pubitemid 23239983)